

Pharmacy Benefit Consultants

in two placebo-controlled, parallel-group studies of 1,000 patients with ibs-d, this selective 5-ht₃ antagonist increased self-reported global assessment of relief of ibs symptoms

pharmacy benefit consultants linda cahn

pharmacy benefit consultants